The closing price of Humacyte Inc (NASDAQ: HUMA) was $2.87 for the day, down -0.35% from the previous closing price of $2.88. On the day, 745401 shares were traded.
Ratios:
Our analysis of HUMA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.52 and its Current Ratio is at 4.52. In the meantime, Its Debt-to-Equity ratio is 4.29 whereas as Long-Term Debt/Eq ratio is at 4.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 11, 2023, initiated with a Buy rating and assigned the stock a target price of $6.
On August 14, 2023, Piper Sandler Upgraded its rating to Neutral which previously was Underweight and also upped its target price recommendation from $2.75 to $3.50.
On June 22, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $6.Cantor Fitzgerald initiated its Overweight rating on June 22, 2023, with a $6 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 14 ’23 when Dougan Brady W sold 2,000,000 shares for $2.78 per share. The transaction valued at 5,560,000 led to the insider holds 6,191,140 shares of the business.
Niklason Laura E sold 2,000,000 shares of HUMA for $5,560,000 on Sep 14 ’23. The President, CEO and Director now owns 6,191,140 shares after completing the transaction at $2.78 per share. On Aug 21 ’23, another insider, Ayabudge LLC, who serves as the 10% Owner of the company, sold 602,443 shares for $3.39 each. As a result, the insider received 2,042,282 and left with 8,191,140 shares of the company.
Stock Price History:
Over the past 52 weeks, HUMA has reached a high of $5.60, while it has fallen to a 52-week low of $1.96.
Shares Statistics:
A total of 103.67M shares are outstanding, with a floating share count of 89.92M. Insiders hold about 24.49% of the company’s shares, while institutions hold 14.95% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by Humana Inc. analysts. The consensus estimate for the next quarter is $2.31, with high estimates of $4.47 and low estimates of $2.87.
Analysts are recommending an EPS of between $Communication Services and $Healthcare for the fiscal current year, implying an average EPS of $Energy.
